1869057-83-9 Usage
Property
Novel small molecule inhibitor of EGFR
Property
Targets the T790M mutation
Property
Promising antitumor activity
Property
Entered clinical trials
Property
Acceptable safety profile
Property
New treatment option for NSCLC with T790M mutation
Content
Alflutinib
Content
T790M mutation
Content
Preclinical studies
Content
Clinical trials
Content
Mild to moderate adverse effects
Content
New treatment option
Explanation
Alflutinib is a novel drug that inhibits the epidermal growth factor receptor, which is a key protein involved in the growth and spread of cancer cells.
Explanation
Alflutinib has been specifically designed to target the T790M mutation, which is known to cause resistance to first-generation EGFR inhibitors in NSCLC patients.
Explanation
Alflutinib has shown promising results in preclinical studies in terms of its ability to inhibit tumor growth in NSCLC.
Explanation
Alflutinib has moved into clinical trials to evaluate its efficacy and safety in NSCLC patients.
Explanation
Clinical trials have reported mild to moderate adverse effects associated with alflutinib, indicating that it may be tolerable for patients.
Explanation
Alflutinib has the potential to provide a new treatment option for NSCLC patients with the T790M mutation, addressing the issue of resistance to traditional EGFR inhibitors.
Check Digit Verification of cas no
The CAS Registry Mumber 1869057-83-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,6,9,0,5 and 7 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1869057-83:
(9*1)+(8*8)+(7*6)+(6*9)+(5*0)+(4*5)+(3*7)+(2*8)+(1*3)=229
229 % 10 = 9
So 1869057-83-9 is a valid CAS Registry Number.
1869057-83-9Relevant academic research and scientific papers
SALT OF PYRIDINYL AMINO PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
-
, (2019/01/29)
A mesylate salt of a compound represented by formula (I) and preparation method therefor, a pharmaceutical composition containing the salt, and an application of the salt in the treatment of activated EGFR mutant- or drug-resistant mutant-mediated diseases, especially cancer, in mammals, particularly humans. The mesylate salt of the compound represented by formula (I) has high bioavailability in animals, can better inhibit the growth of transplanted tumors in animals, and demonstrates desirable safety.
CRYSTALLINE FORMS OF MESYLATE SALT OF PYRIDINYL AMINO PYRIMIDINE DERIVATIVE, PREPARATION METHODS THEREFOR, AND APPLICATIONS THEREOF
-
, (2019/04/14)
Forms I and II of the mesylate salt of the compound of formula (I), a preparation methods thereof, a pharmaceutical composition containing the crystal forms, and the use of the crystal forms in treating diseases mediated by activating and resistance mutations of EGFR, in particular cancer, in mammal, in particular in human. The crystal forms of the mesylate salt of the compound of formula (I) have good solubilities and high bioavailabilities in animals.
PYRIDINE AMIDOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
-
Paragraph 0190; 0191; 0192; 0206; 0207; 0208, (2017/07/14)
The present invention relates to pyridinylaminopyrimidine derivatives represented by the following formula (I), and pharmaceutically acceptable salts, preparation process and use thereof, wherein R1, R2, R3, R4,
